Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

NCT01575925 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Renal Impairment

Interventions

DRUG: 4 mg Oral POM + 40 mg Oral DEX
DRUG: 2 mg Oral POM + 40 mg Oral DEX

Sponsor

Celgene